Physician profile
Tammy H Le
NPI 1417273830
$9,508.18
in general payments reported to CMS, 2019-2025
34 companies · $2,205 in 2025
The $2,205 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $286 · 2021: $960 · 2022: $1,445 · 2023: $2,080 · 2024: $2,206 · 2025: $2,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,282 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,281.92 |
| Education | $208.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,029.32 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,605.71 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Amgen INC. | $859.79 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $769.98 | 2021-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $566.41 | 2021-2025 | Dupixent |
| Genzyme Corporation | $434.60 | 2020-2025 | |
| Grifols USA, LLC | $402.13 | 2021-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.52 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Verona Pharma, INC. | $237.94 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $224.72 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $212.29 | 2019-2024 | |
| Baxter Healthcare | $138.22 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Biohaven Pharmaceuticals, INC. | $118.49 | 2021 | |
| Electromed, INC. | $88.20 | 2025 | Smartvest |
| Genentech USA, INC. | $68.36 | 2021-2023 | Xolair |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $45.63 | 2023 | Arikayce |
| Gilead Sciences, INC. | $43.15 | 2021 | |
| Allergan, INC. | $37.58 | 2019-2020 | |
| Advanced Respiratory, INC | $35.50 | 2020-2021 | |
| Caris Mpi, INC. | $34.63 | 2025 | Mi Cancer Seek |
| Actelion Pharmaceuticals US, INC. | $28.07 | 2024 | Uptravi, Opsumit |
| United Therapeutics Corporation | $22.52 | 2024 | Tyvaso |
| Tactile Systems Technology INC | $22.48 | 2022 | |
| Inspire Medical Systems, INC. | $21.51 | 2024 | Inspire |
| Jazz Pharmaceuticals INC. | $20.66 | 2021 | |
| Pulmonx Corporation | $19.47 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.95 | 2021 | |
| Lilly USA, LLC | $18.87 | 2021 | |
| Abbvie INC. | $18.39 | 2023 | |
| Janssen Pharmaceuticals, INC | $18.12 | 2024 | Xarelto |
| Ambu INC. | $17.58 | 2020 | |
| Merck Sharp & Dohme LLC | $16.35 | 2021 | |
| Pfizer INC. | $16.14 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.